Skip to main content

6 Result(s)

within A. V. Misyurin Remove this filter

and

  1. No Access

    Article

    Development of a Humanized Antibody 5D3Hu against the PRAME Tumor Antigen

    The PRAME antigen, which is a significant target for monoclonal antibodies, is a tumor-specific marker that is active at all stages of tumor cell differentiation; it induces a spontaneous T-cell response. In t...

    M. V. Larina, Y. P. Finashutina, N. A. Lyzhko… in Russian Journal of Bioorganic Chemistry (2022)

  2. No Access

    Article

    Detection of the PRAME Protein on the Surface of Melanoma Cells Using a Fluorescently Labeled Monoclonal Antibody

    Determination of the expression level of tumor marker PRAME protein is important both for predicting the course of the disease and for monitoring the effectiveness of anticancer therapy. A fluorescently labele...

    K. A. Sapozhnikova, A. V. Misyurin, N. B. Pestov… in Russian Journal of Bioorganic Chemistry (2021)

  3. No Access

    Article

    Monoclonal Antibodies to PRAME Protein Slow the Development of PRAME-Expressing Tumor

    Two monoclonal antibodies recognizing non-overlap** epitopes of the PRAME protein were injected into immunocompetent mice to study their influence on the growth of subcutaneous tumor nodes. The B16F10 murine...

    O. N. Solopova, Yu. P. Finashutina, N. N. Kasatkina… in Doklady Biochemistry and Biophysics (2021)

  4. No Access

    Article

    Epitope Analysis of Murine and Chimeric Monoclonal Antibodies Recognizing the Cancer Testis Antigen PRAME

    We investigated the epitope specificity of different monoclonal antibodies recognizing the cancer testis antigen PRAME. Antibody 5D3 binds to the fragment of PRAME corresponding to 160–180 amino acid residues....

    V. A. Misyurin, Yu. P. Finashutina, A. A. Turba… in Doklady Biochemistry and Biophysics (2020)

  5. No Access

    Article

    Cancer-testis gene expression profile in human melanoma cell lines

    A growing number of evidence indicates that cancer-testis antigens (CTA) can be used as specific targets for immune therapy of malignant melanoma. The aim of this study was to provide a basis for selecting the...

    V. A. Misyurin, A. V. Misyurin, A. E. Lukina… in Biochemistry (Moscow) Supplement Series A:… (2014)

  6. No Access

    Article

    Three Novel Mutations in Porphobilinogen Deaminase Gene Identified in Russian Patients with Acute Intermittent Porphyria

    Porphobilinogen deaminase (PBGD) is a key enzyme of the heme biosynthetic pathway. Defects in the PBGD gene lead to an autosomal dominant disease, acute intermittent porphyria (AIP). Almost all AIP patients wi...

    V. L. Surin, A. V. Luk'yanenko, I. V. Karpova… in Russian Journal of Genetics (2001)